

Ramesh Rengan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/181426/publications.pdf>

Version: 2024-02-01

127
papers

5,975
citations

109321

35
h-index

76900

74
g-index

130
all docs

130
docs citations

130
times ranked

8933
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. <i>Nature</i> , 2015, 520, 373-377.	27.8	1,955
2	Predicting Radiation Pneumonitis After Chemoradiation Therapy for Lung Cancer: An International Individual Patient Data Meta-analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 444-450.	0.8	545
3	Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 146, 223-229.	0.6	168
4	Predicting Esophagitis After Chemoradiation Therapy for Non-Small Cell Lung Cancer: An Individual Patient Data Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 690-696.	0.8	157
5	Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 70-75.	0.8	149
6	Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 741-747.	0.8	146
7	Central-Airway Necrosis after Stereotactic Body-Radiation Therapy. <i>New England Journal of Medicine</i> , 2012, 366, 2327-2329.	27.0	134
8	Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 505-516.	0.8	125
9	Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. <i>Annals of Translational Medicine</i> , 2020, 8, 482-482.	1.7	101
10	Stereotactic Body Radiation Therapy for Lung Cancer. <i>Chest</i> , 2013, 143, 1784-1790.	0.8	87
11	Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals. <i>Aids</i> , 2013, 27, 459-468.	2.2	86
12	Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient hematopoietic cells. <i>Blood</i> , 2000, 95, 1283-1292.	1.4	83
13	Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 281-292.	1.1	82
14	Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes. <i>Radiotherapy and Oncology</i> , 2010, 95, 178-184.	0.6	79
15	Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BE235. <i>Molecular Pharmacology</i> , 2012, 82, 1230-1240.	2.3	78
16	A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response. <i>Journal of Thoracic Oncology</i> , 2012, 7, 709-715.	1.1	68
17	Stage Migration in Planning PET/CT Scans in Patients Due to Receive Radiotherapy for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 79-85.	2.6	61
18	Prospective study of proton beam radiation therapy for limited-stage small cell lung cancer. <i>Cancer</i> , 2017, 123, 4244-4251.	4.1	60

#	ARTICLE	IF	CITATIONS
19	The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1454-1460.	1.1	58
20	The Use of Proton Therapy in the Treatment of Lung Cancers. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 427-432.	2.0	57
21	Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy. <i>Medical Physics</i> , 2017, 44, 3418-3429.	3.0	55
22	Intensity-Modulated Proton Therapy for Elective Nodal Irradiation and Involved-Field Radiation in the Definitive Treatment of Locally Advanced Non-Small-Cell Lung Cancer: A Dosimetric Study. <i>Clinical Lung Cancer</i> , 2015, 16, 237-244.	2.6	54
23	Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients. <i>Practical Radiation Oncology</i> , 2019, 9, 305-321.	2.1	51
24	Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. <i>Lancet Oncology</i> , The, 2012, 13, 1203-1209.	10.7	50
25	Impact of PET Staging in Limited-Stage Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 899-905.	1.1	49
26	Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 612-620.	0.8	49
27	Distal cT2N0 Rectal Cancer: Is There an Alternative to Abdominoperineal Resection?. <i>Journal of Clinical Oncology</i> , 2005, 23, 4905-4912.	1.6	48
28	Effect of Body Mass Index on Magnitude of Setup Errors in Patients Treated With Adjuvant Radiotherapy for Endometrial Cancer With Daily Image Guidance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 670-675.	0.8	44
29	A moving target: Image guidance for stereotactic body radiation therapy for early-stage non-small cell lung cancer. <i>Practical Radiation Oncology</i> , 2013, 3, 307-315.	2.1	43
30	Definitive Radiotherapy for Unresected Adenoid Cystic Carcinoma of the Trachea. <i>Chest</i> , 2012, 141, 1323-1326.	0.8	42
31	Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 631-640.	0.8	40
32	An in-silico comparison of proton beam and IMRT for postoperative radiotherapy in completely resected stage IIIA non-small cell lung cancer. <i>Radiation Oncology</i> , 2013, 8, 144.	2.7	39
33	First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 364-371.	2.6	38
34	Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions. <i>Cancers</i> , 2015, 7, 1178-1190.	3.7	37
35	Brachial Plexopathy in Apical Non-Small Cell Lung Cancer Treated With Definitive Radiation: Dosimetric Analysis and Clinical Implications. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 175-181.	0.8	36
36	Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-Small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location. <i>Clinical Lung Cancer</i> , 2019, 20, e63-e71.	2.6	36

#	ARTICLE	IF	CITATIONS
37	Adjuvant radiotherapy for completely resected stage 2 thymoma. <i>Cancer</i> , 2011, 117, 3502-3508.	4.1	35
38	Radiation Injury to the Normal Brain Measured by 3Dâ€Echoâ€Planar Spectroscopic Imaging and Diffusion Tensor Imaging: Initial Experience. <i>Journal of Neuroimaging</i> , 2015, 25, 97-104.	2.0	35
39	Combination of stereotactic ablative body radiation with targeted therapies. <i>Lancet Oncology</i> , The, 2014, 15, e426-e434.	10.7	32
40	Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 114-121.	2.8	32
41	COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation. <i>Brachytherapy</i> , 2020, 19, 401-411.	0.5	32
42	Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. <i>Practical Radiation Oncology</i> , 2019, 9, 280-288.	2.1	31
43	Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma. <i>Cancer Biology and Therapy</i> , 2010, 10, 425-429.	3.4	29
44	High body mass index is associated with worse quality of life in breast cancer patients receiving radiotherapy. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 125-133.	2.5	29
45	Dynamic simulation of motion effects in IMAT lung SBRT. <i>Radiation Oncology</i> , 2014, 9, 225.	2.7	28
46	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 180-188.	2.8	28
47	Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Nonâ€Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1464.	7.1	28
48	Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. <i>Translational Lung Cancer Research</i> , 2018, 8, 5-14.	2.8	27
49	Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 410-418.	2.0	24
50	Stereotactic Body Radiotherapy. <i>Seminars in Oncology</i> , 2014, 41, 776-789.	2.2	22
51	ACRâ€ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 545-552.	1.3	20
52	Integrating the Healthcare Enterprise in Radiation Oncology Plug and Playâ€The Future of Radiation Oncology?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 333-336.	0.8	19
53	Radiation Therapy in King County, Washington During the COVID-19 Pandemic: Balancing Patient Care, Transmission Mitigation, and Resident Training. <i>Advances in Radiation Oncology</i> , 2020, 5, 544-547.	1.2	19
54	Clinical target promiscuity: lessons from ras molecular trials. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 403-414.	5.9	18

#	ARTICLE	IF	CITATIONS
55	Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Dosimetric Comparison of Two Well-Described Techniques. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1431-1437.	1.1	18
56	Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study. <i>Practical Radiation Oncology</i> , 2015, 5, e355-e363.	2.1	18
57	Long-term Neck Control Rates After Complete Response to Chemoradiation in Patients With Advanced Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 465-469.	1.3	17
58	New Strategies in Non-Small Cell Lung Cancer: Improving Outcomes in Chemoradiotherapy for Locally Advanced Disease. <i>Clinical Cancer Research</i> , 2011, 17, 4192-4199.	7.0	17
59	Is Intermediate Radiation Dose Escalation With Concurrent Chemotherapy for Stage III Non-Small-Cell Lung Cancer Beneficial? A Multi-Institutional Propensity Score Matched Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 133-139.	0.8	17
60	Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1255-1264.	0.8	17
61	Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 635-643.	0.8	17
62	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. <i>Oncolimmunology</i> , 2021, 10, 1863631.	4.6	16
63	Ten-Year Results of Preoperative Radiation Followed by Sphincter Preservation for Rectal Cancer: Increased Local Failure Rate in Nonresponders. <i>Clinical Colorectal Cancer</i> , 2006, 5, 413-421.	2.3	15
64	The Impact of Extent and Location of Mediastinal Lymph Node Involvement on Survival in Stage III Non-Small Cell Lung Cancer Patients Treated With Definitive Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 340-347.	0.8	15
65	Radiation Dosimetry and Biodistribution of the Hypoxia Tracer ¹⁸ F-EF5 in Oncologic Patients. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 412-419.	1.0	15
66	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. <i>International Journal of Particle Therapy</i> , 2018, 5, 183-195.	1.8	15
67	Can we predict reactivity for aromatic nucleophilic substitution with [¹⁸ F]fluoride ion?. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1993, 33, 563-572.	1.0	14
68	Prognostic Value of Primary Tumor FDG Uptake for Occult Mediastinal Lymph Node Involvement in Clinically N2/N3 Node-negative Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 135-139.	1.3	14
69	Comparison of regional lung perfusion response on longitudinal MAA SPECT/CT in lung cancer patients treated with and without functional tissue-avoidance radiation therapy. <i>British Journal of Radiology</i> , 2019, 92, 20190174.	2.2	14
70	Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate. <i>Oncology Letters</i> , 2014, 7, 1151-1158.	1.8	13
71	A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 170-177.	0.8	13
72	The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients. <i>Advances in Radiation Oncology</i> , 2017, 2, 192-196.	1.2	12

#	ARTICLE	IF	CITATIONS
73	International Outreach: What Is the Responsibility of ASTRO and the Major International Radiation Oncology Societies?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 481-484.	0.8	11
74	Oligometastatic non-small-cell lung cancer: current treatment strategies. <i>Lung Cancer: Targets and Therapy</i> , 2016, Volume 7, 129-140.	2.7	11
75	Consensus Statement on Proton Therapy in Mesothelioma. <i>Practical Radiation Oncology</i> , 2021, 11, 119-133.	2.1	11
76	Addressing connectivity issues: The Integrating the Healthcare Enterprise-Radiation Oncology (IHE-RO) initiative. <i>Practical Radiation Oncology</i> , 2011, 1, 226-231.	2.1	10
77	Ill-posed problem and regularization in reconstruction of radiobiological parameters from serial tumor imaging data. <i>Physics in Medicine and Biology</i> , 2015, 60, 8491-8503.	3.0	10
78	Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 5027-5037.	7.0	10
79	Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy. <i>Cureus</i> , 2017, 9, e1705.	0.5	10
80	Regulation of Oscillations in Filamentous Actin Content in Polymorphonuclear Leukocytes Stimulated with Leukotriene B4 and Platelet-Activating Factor. <i>Biochemical and Biophysical Research Communications</i> , 1999, 262, 479-486.	2.1	9
81	New Approaches to Radiotherapy as Definitive Treatment for Inoperable Lung Cancer. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2008, 20, 188-197.	0.6	9
82	Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 122-133.	2.8	9
83	Scanning Beam Proton Therapy versus Photon IMRT for Stage III Lung Cancer: Comparison of Dosimetry, Toxicity, and Outcomes. <i>Advances in Radiation Oncology</i> , 2020, 5, 434-443.	1.2	9
84	Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, 861-871.	1.3	9
85	Prospective assessment of demographic characteristics associated with worse health related quality of life measures following definitive chemoradiation in patients with locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 332-339.	2.8	8
86	Sensitivity analysis of FDG PET tumor voxel cluster radiomics and dosimetry for predicting mid-chemoradiation regional response of locally advanced lung cancer. <i>Physics in Medicine and Biology</i> , 2020, 65, 205007.	3.0	7
87	Adjuvant Cisplatin and Docetaxel for Non-small Cell Lung Cancer: The Hospital of the University of Pennsylvania Experience. <i>Journal of Thoracic Oncology</i> , 2010, 5, 667-672.	1.1	6
88	Radiation and Modulation of the Tumor Immune Microenvironment in Nonâ€“Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 133-139.	2.2	6
89	Introduction: Nonâ€“Small-Cell Lung Cancer and Pleural Malignancies: The End of the Era of Therapeutic Nihilism?. <i>Seminars in Radiation Oncology</i> , 2010, 20, 147-148.	2.2	5
90	4D computed tomography scans for conformal thoracic treatment planning: is a single scan sufficient to capture thoracic tumor motion?. <i>Physics in Medicine and Biology</i> , 2018, 63, 02NT03.	3.0	5

#	ARTICLE	IF	CITATIONS
91	Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience. <i>Advances in Radiation Oncology</i> , 2019, 4, 70-78.	1.2	5
92	Treatment of ocular tumors through a novel applicator on a conventional proton pencil beam scanning beamline. <i>Scientific Reports</i> , 2022, 12, 4648.	3.3	5
93	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. <i>Translational Lung Cancer Research</i> , 2007, 6, 169-177.	2.8	4
94	A Glimpse of the Future. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 190-194.	2.0	4
95	Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2003-2004.	1.6	4
96	Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. <i>Radiation Oncology</i> , 2018, 13, 179.	2.7	4
97	Volume effects in the TCP for hypoxic and oxygenated tumors. <i>Medical Physics</i> , 2020, 47, 4626-4633.	3.0	4
98	The Practicality of ICRU and Considerations for Future ICRU Definitions. <i>Seminars in Radiation Oncology</i> , 2018, 28, 201-206.	2.2	4
99	Impact of sociodemographic factors on the radiotherapeutic management of lung cancer: Results of a Quality Research in Radiation Oncology Survey. <i>Practical Radiation Oncology</i> , 2014, 4, e167-e179.	2.1	3
100	Education and Training Needs in Radiation Oncology in India: Opportunities for Indo-US Collaborations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 957-960.	0.8	3
101	The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e205-e209.	2.6	3
102	Phase II Trial of Flaxseed to Prevent Acute Complications After Chemoradiation for Lung Cancer. <i>Journal of Alternative and Complementary Medicine</i> , 2021, 27, 824-831.	2.1	3
103	Multi-institutional study of reirradiation with proton beam radiotherapy for non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7578-7578.	1.6	3
104	Role of particle beam therapy in a trimodality approach to locally advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2013, 4, 95-101.	1.9	2
105	Dose Escalation Optimization in Patients With Locally Advanced Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1365.	7.1	2
106	Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes. <i>Physics in Medicine and Biology</i> , 2021, 66, 125010.	3.0	2
107	Clinical Outcomes After Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of a Multi-institutional Prospective Registry. <i>Advances in Radiation Oncology</i> , 2021, 7, 100767.	1.2	2
108	Uncommon Thoracic Tumors. , 2012, , 859-889.		2

#	ARTICLE	IF	CITATIONS
109	Dietary Flaxseed in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation. Journal of Pulmonary & Respiratory Medicine, 2013, 03, 154.	0.1	2
110	(S010) Stereotactic Body Radiotherapy (SBRT) for Operable vs. Medically Inoperable Stage I Non-Small Cell Lung Cancer: Long-Term Five-Year Outcomes and an Assessment by Fractionation Regimen, Tumor Size, and Tumor Location. International Journal of Radiation Oncology Biology Physics, 2017, 98, E3-E4.	0.8	1
111	Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 374-382.	0.8	1
112	Intratumoral G100 Rescues Radiation-Induced T Cell Depletion and Has Synergistic Anti-Tumor Effect with Local Irradiation in A20 Lymphoma. Blood, 2016, 128, 4166-4166.	1.4	1
113	Uncommon Thoracic Tumors. , 2016, , 865-894.e8.		0
114	Implementation of patient reported outcomes in definitive chemoradiation for non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 154-155.	2.8	0
115	Radiation Treatment of Non-Small Cell Lung Cancer. Seminars in Radiation Oncology, 2021, 31, 95-96.	2.2	0
116	Definitive thoracic radiotherapy in oligometastatic stage IV non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, e18032-e18032.	1.6	0
117	Disparities in the treatment and outcomes of lung cancer among HIV-infected people in Texas.. Journal of Clinical Oncology, 2012, 30, 6070-6070.	1.6	0
118	Impact of PET staging in limited-stage SCLC.. Journal of Clinical Oncology, 2012, 30, 7098-7098.	1.6	0
119	A strategy to reduce acute toxicity from chemoradiation therapy for limited-stage small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, e17534-e17534.	1.6	0
120	Case-control study of prophylactic cranial irradiation in nonmetastatic non-small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, 7050-7050.	1.6	0
121	Abstract 2858: Radiation and dual immune checkpoint blockade overcome tumor resistance and distinctly improve immunity. , 2015, , .		0
122	Abstract A52: Radiation and dual PD-L1 and CTLA4 checkpoint blockade non-redundantly improves tumor resistance, response, and immunity. , 2015, , .		0
123	Long-term results of a phase I/II trial of nelfinavir with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 8552-8552.	1.6	0
124	Prognostic role of mid-treatment PET/CT and plasma cytokines in patients undergoing chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC).. Journal of Clinical Oncology, 2020, 38, 9040-9040.	1.6	0
125	Actionable policy barriers for receiving standard of care treatment among unresected stage III non-small cell lung cancer (NSCLC) patients in the United States.. Journal of Clinical Oncology, 2020, 38, 2069-2069.	1.6	0
126	Concurrent and sequential chemoradiation therapy are associated with improved survival among unresected stage III non-small cell lung cancer patients in the United States.. Journal of Clinical Oncology, 2020, 38, 7043-7043.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Prognostic value of early FDG PET response imaging and peripheral immunologic biomarkers: sub-study of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2021, 7, 100857.	1.2	0